For many families in malaria-affected parts of the world, keeping children safe means using several kinds of protection: mosquito nets, prompt testing and treatment, and medicines in places where health authorities recommend them. Now, in more countries, there is another tool to add: a vaccine designed to protect young children from malaria.
The development is a major step in the long effort to prevent a disease that is especially dangerous for children under five. The World Health Organization (WHO) has recommended two malaria vaccines, RTS,S and R21, for children living in areas with moderate or high transmission of Plasmodium falciparum, the parasite responsible for the most severe form of the disease.
For kids, the big idea is simple: a vaccine can help the body prepare to recognize a threat before an infection happens. For scientists and health workers, getting to this point took years of research, testing and planning.
Why a malaria vaccine matters
Malaria is spread to people through bites from infected mosquitoes. It is preventable and treatable, but it remains a serious health challenge in many countries. The WHO says young children are among the groups at greatest risk of severe illness.
Bed nets, mosquito control, medicines and quick access to diagnosis and treatment remain important. A vaccine does not replace them. Instead, it gives health services another way to reduce children’s risk—particularly in communities where malaria is common and exposure can happen repeatedly.
That extra layer matters because malaria prevention has never depended on one solution alone. A child might sleep under a treated net and still be bitten at another time or place. Vaccination adds protection that works through the child’s immune system, alongside other measures recommended by local health authorities.
Two vaccines reached the recommendation stage
In October 2021, the WHO recommended RTS,S for children at risk in areas where malaria transmission is moderate to high. It was the first malaria vaccine to receive a WHO recommendation. In October 2023, the organization recommended a second vaccine, R21/Matrix-M, for the same broad purpose.
Having two recommended vaccines is useful for a practical reason as well as a scientific one: more than one product can help increase the amount available for vaccination programs. The vaccines are not identical, but both are intended to protect children against malaria caused by P. falciparum. Health authorities decide how to introduce them and which schedule fits local needs.
These are childhood vaccines delivered in several doses, rather than a one-time shot that makes a child permanently immune. The timing is set by health programs, which can fit vaccination into routine visits or, in some places, align doses with seasons when malaria risk is especially high. Families should follow the schedule given by their local health workers.
From a research milestone to community clinics
A recommendation is an important scientific and public-health milestone, but it is not the same as putting a vaccine within reach of every child who could benefit. Countries need supplies, trained health workers, community information and delivery plans that work in local conditions.
One early example came in January 2024, when Cameroon began offering a malaria vaccine through its routine childhood immunization program. It was the first country to do so. The step showed how a vaccine developed and assessed through research could move into ordinary health services, where parents already take children for other recommended vaccinations.
Before broader rollouts, RTS,S was evaluated through a pilot program in Ghana, Kenya and Malawi beginning in 2019. The WHO reported that the program had reached more than two million children with at least one dose. Its evaluation also found a 13% reduction in all-cause mortality among children in the age groups eligible for vaccination in areas where the vaccine was introduced. That result is encouraging, though it describes the pilot setting and should not be read as a promise about what will happen in every community.
The pilot offered more than a measure of vaccine impact. It also gave health services experience with practical questions: how to reach eligible children, how to explain the vaccine to caregivers and how to deliver doses alongside other childhood health services.
A promising tool, not a finish line
There is no single magic answer to malaria. Vaccines reduce risk, but they do not prevent every infection. Children still need other protections, and anyone who becomes ill needs access to testing and appropriate treatment. Health workers can advise families about the measures recommended where they live.
That is why this is good news in a grounded sense. It is not a claim that malaria has disappeared. It is evidence that science has produced another useful way to protect children—and that countries are beginning to build it into the care families can access.
For a child, a vaccination visit may be a small moment. For a community, making those visits available can add up to a broader shield: one made from research, public health planning and the everyday work of caregivers and health workers. The vaccines are one part of that effort, but an important new part.
